# S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer

> **NCT02131493** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** S-1, Gemcitabine

## Key facts

- **NCT ID:** NCT02131493
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2021-06
- **Final completion:** 2021-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131493, "S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02131493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*